David Sinclair

Co-Founder at Life Biosciences LLC

David Sinclair

David Sinclair

Co-Founder at Life Biosciences LLC

Overview
Career Highlights

Life Biosciences LLC
Cohbar, Inc.
Arc Bio LLC

RelSci Relationships

1690

Number of Boards

2

Birthday

1969

Age

51

Number of Awards

1

Relationships
RelSci Relationships are individuals David Sinclair likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder & Director at Cohbar, Inc.

Relationship likelihood: Strong

Founder at Cohbar, Inc.

Relationship likelihood: Strong

Academic Dean, USC Davis School of Gerontology at University of Southern California

Relationship likelihood: Strong

Managing Director at General Atlantic Service Co. LP

Relationship likelihood: Strong

Co-Founder at Life Biosciences LLC

Relationship likelihood: Strong

Chief Executive Officer at Life Biosciences, Inc.

Relationship likelihood: Strong

Chairman of the Board, Co-Founder at Concert Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder & General Partner at Longwood Fund Management LLC

Relationship likelihood: Strong

Chief Executive Officer at Alkermes Plc

Relationship likelihood: Strong

Consulting Professor, Department of Chemistry at Stanford University

Relationship likelihood: Strong

Paths to David Sinclair
Potential Connections via
Relationship Science
You
David Sinclair
Co-Founder at Life Biosciences LLC
Education
Ph.D Genetics, Molecular Biology, Biochemistry, Marine Biology

The University of New South Wales (UNSW) is an Australian public university. Established in 1949, it is ranked among the top 60 universities in the world according to the QS World University Rankings. It has more than 50,000 students from over 120 countries. The main UNSW campus is located on a 38 hectare site at Kensington, seven kilometres from the centre of Sydney. Other campuses are the College of Fine Arts in Paddington, UNSW@ADFA, the University College at the Australian Defence Force Academy in Canberra, and sub-campuses at Randwick and Coogee in Sydney, as well as research stations around NSW. UNSW is a founding member of the Group of Eight, a coalition of Australian research-intensive universities, and of the international network Universitas 21. UNSW graduates hold more chief executive positions of ASX 200 listed companies than those of any other university in Australia.

Career History
Co-Founder
2017 - Current

Life Biosciences LLC engages in the provision of research on aging and age-related diseases. It focuses on altered communication and inflammation, chromosomal instability, cellular senescence, loss of protoeostasis, metabolism, stem cell exhaustion, epigenetic alterations, and mitochondrial dysfunction. The company was founded by David Sinclair and Tristan Alexander Edwards in 2017 and is headquartered in Boston, MA.

Founder
2007 - Current

CohBar, Inc. engages in the research and development of mitochondria-based therapeutics. It focuses on treatments of diseases, which include diabetes, obesity, fatty liver disease and non-alcoholic steatohepatitis, cancer, Alzheimer's disease, and atherosclerosis. The company was founded by Nir Barzilai, Pinchas Cohen, David Sinclair, John Amatruda, and Laura Cobb on October 19, 2007 and is headquartered in Menlo Park, CA.

Co-Founder
Current
Boards & Committees
Non-Executive Director
2019 - Current

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Member, Scientific Advisory Board
2018 - Current

Zymo Research Corp. is an American private company. The firm manufactures and distributes molecular biology research tools.The company says this about itself: Zymo Research is privately owned and has been serving the scientific community with state-of-the-art molecular biology tools since 1994. \"The Beauty of Science is to Make Things Simple\" is their motto, which is reflected in every product they produce, from their epigenetics to DNA/RNA purification technologies. Historically recognized as the leader in epigenetics, Zymo Research is breaking boundaries with novel solutions for sample collection and microbiomic measurements. It is the first company to develop microbiomics solutions, from collection to conclusion, based on new rigorous standards for microbiomic measurements. The scientists at Zymo Research have been leading the initiative to improve reproducibility and accuracy in this field by developing the first commercially available microbiome (mock microbial community) standards.

Chairman
2017 - Current

Life Biosciences LLC engages in the provision of research on aging and age-related diseases. It focuses on altered communication and inflammation, chromosomal instability, cellular senescence, loss of protoeostasis, metabolism, stem cell exhaustion, epigenetic alterations, and mitochondrial dysfunction. The company was founded by David Sinclair and Tristan Alexander Edwards in 2017 and is headquartered in Boston, MA.

Director
Current

ENHANCE THE QUALITY OF LIFE AND ALLEVIATE SUFFERING BY SUPPORTING BIOMEDICAL RESEARCH ON AGING.

Political Donations
$250
2012

Representative from Illinois's 11th Congressional District

$1,500
2008

Former Senator from Massachusetts

$2,000
2008

Representative from Indiana's 1st Congressional District

Transactions
Details Hidden

Life Biosciences LLC raised money in a private placement transaction

Investments
Details Hidden

Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas.Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases.Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass.Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA.

Awards & Honors
2014
TIME - 100 Most Influential People in the World
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by David Sinclair. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of David Sinclair's profile does not indicate a business or promotional relationship of any kind between RelSci and David Sinclair.